Latest algorithm (Shield V2) has sensitivity of 84% for colorectal cancer with specificity of 90%, with stage I sensitivity of 62% Performance of the Shield algorithm was validated in expanded ...
Investing.com - Guardant Health (NASDAQ:GH) shares declined after Raymond James maintained its Outperform rating and $61.00 price target despite the company’s Shield V2 algorithm update showing less ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback